Effects of lovastatin on cognitive function and psychological well-being

Matthew F. Muldoon, Steven D Barger, Christopher M. Ryan, Janine D. Flory, John P. Lehoczky, Karen A. Matthews, Stephen B. Manuck

Research output: Contribution to journalArticle

210 Citations (Scopus)

Abstract

PURPOSE: Animal research and cross-sectional studies suggest that serum lipid concentrations may influence cognitive function, mood, and behavior, but few clinical trials have studied these effects.SUBJECTS AND METHODS: In this double-blind investigation, 209 generally healthy adults with a serum low-density-lipoprotein (LDL) cholesterol level of 160 mg/dL or higher were randomly assigned to 6-month treatment with lovastatin (20 mg) or placebo. Assessments of neuropsychological performance, depression, hostility, and quality of life were conducted at baseline and at the end of the treatment period. Summary effect sizes were estimated as z scores on a standard deviation (SD) scale. RESULTS: Placebo-treated subjects improved between baseline and posttreatment periods on neuropsychological tests in all five performance domains, consistent with the effects of practice on test performance (all P <0.04), whereas those treated with lovastatin improved only on tests of memory recall (P = 0.03). Comparisons of the changes in performance between placebo- and lovastatin-treated subjects revealed small, but statistically significant, differences for tests of attention (z score = 0.18; 95% confidence interval (CI), 0.06 to 0.31; P = 0.005) and psychomotor speed (z score = 0.17; 95% CI, 0.05 to 0.28; P = 0.004) that were consistent with greater improvement in the placebo group. Psychological well-being, as measured several ways, was not affected by lovastatin. CONCLUSION: Treatment of hypercholesterolemia with lovastatin did not cause psychological distress or substantially alter cognitive function. Treatment did result in small performance decrements on neuropsychological tests of attention and psychomotor speed, the clinical importance of which is uncertain. Copyright (C) 2000 Excerpta Medica Inc.

Original languageEnglish (US)
Pages (from-to)538-546
Number of pages9
JournalAmerican Journal of Medicine
Volume108
Issue number7
DOIs
StatePublished - May 2000

Fingerprint

Lovastatin
Cognition
Psychology
Placebos
Neuropsychological Tests
Confidence Intervals
Hostility
Therapeutics
Hypercholesterolemia
Serum
LDL Cholesterol
Cross-Sectional Studies
Quality of Life
Clinical Trials
Depression
Lipids

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Muldoon, M. F., Barger, S. D., Ryan, C. M., Flory, J. D., Lehoczky, J. P., Matthews, K. A., & Manuck, S. B. (2000). Effects of lovastatin on cognitive function and psychological well-being. American Journal of Medicine, 108(7), 538-546. https://doi.org/10.1016/S0002-9343(00)00353-3

Effects of lovastatin on cognitive function and psychological well-being. / Muldoon, Matthew F.; Barger, Steven D; Ryan, Christopher M.; Flory, Janine D.; Lehoczky, John P.; Matthews, Karen A.; Manuck, Stephen B.

In: American Journal of Medicine, Vol. 108, No. 7, 05.2000, p. 538-546.

Research output: Contribution to journalArticle

Muldoon, MF, Barger, SD, Ryan, CM, Flory, JD, Lehoczky, JP, Matthews, KA & Manuck, SB 2000, 'Effects of lovastatin on cognitive function and psychological well-being', American Journal of Medicine, vol. 108, no. 7, pp. 538-546. https://doi.org/10.1016/S0002-9343(00)00353-3
Muldoon, Matthew F. ; Barger, Steven D ; Ryan, Christopher M. ; Flory, Janine D. ; Lehoczky, John P. ; Matthews, Karen A. ; Manuck, Stephen B. / Effects of lovastatin on cognitive function and psychological well-being. In: American Journal of Medicine. 2000 ; Vol. 108, No. 7. pp. 538-546.
@article{4e3e818a5d16439ba3849f842f82daee,
title = "Effects of lovastatin on cognitive function and psychological well-being",
abstract = "PURPOSE: Animal research and cross-sectional studies suggest that serum lipid concentrations may influence cognitive function, mood, and behavior, but few clinical trials have studied these effects.SUBJECTS AND METHODS: In this double-blind investigation, 209 generally healthy adults with a serum low-density-lipoprotein (LDL) cholesterol level of 160 mg/dL or higher were randomly assigned to 6-month treatment with lovastatin (20 mg) or placebo. Assessments of neuropsychological performance, depression, hostility, and quality of life were conducted at baseline and at the end of the treatment period. Summary effect sizes were estimated as z scores on a standard deviation (SD) scale. RESULTS: Placebo-treated subjects improved between baseline and posttreatment periods on neuropsychological tests in all five performance domains, consistent with the effects of practice on test performance (all P <0.04), whereas those treated with lovastatin improved only on tests of memory recall (P = 0.03). Comparisons of the changes in performance between placebo- and lovastatin-treated subjects revealed small, but statistically significant, differences for tests of attention (z score = 0.18; 95{\%} confidence interval (CI), 0.06 to 0.31; P = 0.005) and psychomotor speed (z score = 0.17; 95{\%} CI, 0.05 to 0.28; P = 0.004) that were consistent with greater improvement in the placebo group. Psychological well-being, as measured several ways, was not affected by lovastatin. CONCLUSION: Treatment of hypercholesterolemia with lovastatin did not cause psychological distress or substantially alter cognitive function. Treatment did result in small performance decrements on neuropsychological tests of attention and psychomotor speed, the clinical importance of which is uncertain. Copyright (C) 2000 Excerpta Medica Inc.",
author = "Muldoon, {Matthew F.} and Barger, {Steven D} and Ryan, {Christopher M.} and Flory, {Janine D.} and Lehoczky, {John P.} and Matthews, {Karen A.} and Manuck, {Stephen B.}",
year = "2000",
month = "5",
doi = "10.1016/S0002-9343(00)00353-3",
language = "English (US)",
volume = "108",
pages = "538--546",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Effects of lovastatin on cognitive function and psychological well-being

AU - Muldoon, Matthew F.

AU - Barger, Steven D

AU - Ryan, Christopher M.

AU - Flory, Janine D.

AU - Lehoczky, John P.

AU - Matthews, Karen A.

AU - Manuck, Stephen B.

PY - 2000/5

Y1 - 2000/5

N2 - PURPOSE: Animal research and cross-sectional studies suggest that serum lipid concentrations may influence cognitive function, mood, and behavior, but few clinical trials have studied these effects.SUBJECTS AND METHODS: In this double-blind investigation, 209 generally healthy adults with a serum low-density-lipoprotein (LDL) cholesterol level of 160 mg/dL or higher were randomly assigned to 6-month treatment with lovastatin (20 mg) or placebo. Assessments of neuropsychological performance, depression, hostility, and quality of life were conducted at baseline and at the end of the treatment period. Summary effect sizes were estimated as z scores on a standard deviation (SD) scale. RESULTS: Placebo-treated subjects improved between baseline and posttreatment periods on neuropsychological tests in all five performance domains, consistent with the effects of practice on test performance (all P <0.04), whereas those treated with lovastatin improved only on tests of memory recall (P = 0.03). Comparisons of the changes in performance between placebo- and lovastatin-treated subjects revealed small, but statistically significant, differences for tests of attention (z score = 0.18; 95% confidence interval (CI), 0.06 to 0.31; P = 0.005) and psychomotor speed (z score = 0.17; 95% CI, 0.05 to 0.28; P = 0.004) that were consistent with greater improvement in the placebo group. Psychological well-being, as measured several ways, was not affected by lovastatin. CONCLUSION: Treatment of hypercholesterolemia with lovastatin did not cause psychological distress or substantially alter cognitive function. Treatment did result in small performance decrements on neuropsychological tests of attention and psychomotor speed, the clinical importance of which is uncertain. Copyright (C) 2000 Excerpta Medica Inc.

AB - PURPOSE: Animal research and cross-sectional studies suggest that serum lipid concentrations may influence cognitive function, mood, and behavior, but few clinical trials have studied these effects.SUBJECTS AND METHODS: In this double-blind investigation, 209 generally healthy adults with a serum low-density-lipoprotein (LDL) cholesterol level of 160 mg/dL or higher were randomly assigned to 6-month treatment with lovastatin (20 mg) or placebo. Assessments of neuropsychological performance, depression, hostility, and quality of life were conducted at baseline and at the end of the treatment period. Summary effect sizes were estimated as z scores on a standard deviation (SD) scale. RESULTS: Placebo-treated subjects improved between baseline and posttreatment periods on neuropsychological tests in all five performance domains, consistent with the effects of practice on test performance (all P <0.04), whereas those treated with lovastatin improved only on tests of memory recall (P = 0.03). Comparisons of the changes in performance between placebo- and lovastatin-treated subjects revealed small, but statistically significant, differences for tests of attention (z score = 0.18; 95% confidence interval (CI), 0.06 to 0.31; P = 0.005) and psychomotor speed (z score = 0.17; 95% CI, 0.05 to 0.28; P = 0.004) that were consistent with greater improvement in the placebo group. Psychological well-being, as measured several ways, was not affected by lovastatin. CONCLUSION: Treatment of hypercholesterolemia with lovastatin did not cause psychological distress or substantially alter cognitive function. Treatment did result in small performance decrements on neuropsychological tests of attention and psychomotor speed, the clinical importance of which is uncertain. Copyright (C) 2000 Excerpta Medica Inc.

UR - http://www.scopus.com/inward/record.url?scp=0034015649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034015649&partnerID=8YFLogxK

U2 - 10.1016/S0002-9343(00)00353-3

DO - 10.1016/S0002-9343(00)00353-3

M3 - Article

VL - 108

SP - 538

EP - 546

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 7

ER -